episindan 10 mg prašak za otopinu za injekciju ili infuziju
teva b.v., swensweg 5, haarlem, nizozemska - epirubicinklorid - prašak za otopinu za injekciju ili infuziju - 10 mg/bočici - urbroj: jedna bočica sadrži 10 mg epirubicinklorida
episindan 50 mg prašak za otopinu za injekciju ili infuziju
teva b.v., swensweg 5, haarlem, nizozemska - epirubicinklorid - prašak za otopinu za injekciju ili infuziju - 50 mg/bočici - urbroj: jedna bočica sadrži 50 mg epirubicinklorida
tolnexa 20 mg/ml koncentrat za otopinu za infuziju
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - docetaksel - koncentrat za otopinu za infuziju - 20 mg/ml - urbroj: 1 ml koncentrata za otopinu za infuziju sadrži 20 mg docetaksela
suxamethonium chlorid vuab 100 mg 100 mg/1 bočica prašak za rastvor za injekciju/infuziju
sanmed d.o.o. banja luka - suksametonijum - prašak za rastvor za injekciju/infuziju - 100 mg/1 bočica - 1 bočica sadrži: 100 mg suksametonijum hlorida
zercepac
accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastična sredstva - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. prije kemoterapije moraju biti uključena barem антрациклина i таксана, ako pacijenti nisu prikladni za tih postupaka. hormon-receptor-pozitivnih bolesnika također mora biti hormonske terapije, ako pacijenti nisu prikladni za tih postupaka. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. u kombinaciju sa docetaxel za liječenje bolesnika koji nisu primali kemoterapiju za метастатической bolesti. u kombinaciji s inhibitor aromataze za liječenje pacijenata u postmenopauzi s hormon-receptor pozitivnim ГБЦ, ne ranije liječenih трастузумаб. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). nakon operacije, kemoterapije (неоадъювантной ili adjuvantne) i radioterapije (ako je primjenjivo). nakon adjuvantne kemoterapije doksorubicin i ciklofosfamid, u kombinaciji s паклитакселом ili docetaxel. u kombinaciji s adjuvantne kemoterapije, koji se sastoji od доцетаксела i карбоплатина. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. treba koristiti točne i dokazane metode analize .
lekadol combo 1000 mg/12,2 mg prašak za oralnu otopinu
sandoz d.o.o., maksimirska 120, zagreb, hrvatska - paracetamol fenilefrinklorid - prašak za oralnu otopinu - urbroj: jedna vrećica sadrži 1000 mg paracetamola i 12,2 mg fenilefrinklorida što odgovara 10 mg fenilefrina
lekadol combo 500 mg/12,2 mg prašak za oralnu otopinu
sandoz d.o.o., maksimirska 120, zagreb, hrvatska - paracetamol fenilefrinklorid - prašak za oralnu otopinu - urbroj: jedna vrećica sadrži 500 mg paracetamola i 12,2 mg fenilefrinklorida što odgovara 10 mg fenilefrina
roctavian
biomarin international limited - valoctocogene roxaparvovec - antihemorrhagics - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).
herwenda
sandoz gmbh - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastična sredstva - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).
herceptin 150mg prašak za koncentrat za rastvor za infuziju
"hoffmann-la roche ltd" d.s.d. podgorica - trastuzumab - prašak za koncentrat za rastvor za infuziju - 150mg